Young adults who used cannabis were more likely to develop depression and attempt suicide than nonusers, although this link didn’t extend to anxiety. (JAMA Psychiatry)
Also tied to depression: chronic rhinosinusitis increased people’s risk of incident depression, and the additional presence of nasal polyps heightened this risk. (JAMA Otolaryngology-Head & Neck Surgery)
As for another condition tied to depression and anxiety, research from the Crohn’s & Colitis Congress found people with inflammatory bowel disease often had fluctuating anxiety and depression symptoms over their disease course. Catch up on all of MedPage Today’s CCC coverage here.
Some patients are having trouble filling prescriptions for their anxiety medication following the shortage of buspirone (Buspar). (New York Times)
Half of the 7.7 million U.S. kids with a mental health disorder aren’t receiving the treatment they need, according to a new report. Alabama, Mississippi, Oklahoma, and Utah were some of the states in the top quartile for prevalence of both mental health disorders and children with a disorder who didn’t receive treatment. (JAMA Pediatrics)
SSRIs may curb the effectiveness of certain opioids, including hydrocodone. “The study results imply that prescribers might instead choose direct acting opioids (e.g., oxycodone or morphine) in depressed patients on SSRIs,” suggested the authors. (PLOS One)
Harmony Bioscience said the FDA granted priority review designation for its narcolepsy treatment, pitolisant.
In other FDA news, the agency also sent 12 warning letters and five advisory letters to companies claiming their “supplements” could prevent or treat Alzheimer’s disease and other conditions.
A proposed bill in Arkansas would add several more conditions that qualify for medical marijuana, including ADD/ADHD, autism, bipolar disorder, chronic insomnia, and generalized anxiety disorder. (KATV)